12:00 AM
 | 
May 31, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Elotuzumab: Phase I data

Data from a Phase I trial in 20 evaluable patients who received >=2 cycles of elotuzumab in combination with Velcade bortezomib showed that 60% of patients achieved at least a minor response and 40% achieved at least a partial response. No dose-limiting toxicities were observed during the first cycle of treatment and the...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >